Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela S Thommen

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Immunity|January 17, 2019
The First Shall (Be) Last: Understanding Durable T Cell Responses in ImmunotherapyDaniela S Thommen
Nature Reviews. Cancer|September 27, 2022
Tumour avatars to model patients' responses to immunotherapyDaniela S Thommen
Nature Cancer|September 22, 2022
Keeping track of the T cells that matterPaulien Kaptein, Daniela S Thommen
Science (New York, N.Y.)|January 6, 2022
Tertiary lymphoid structures in cancerTon N Schumacher, Daniela S Thommen
Nature Reviews. Cancer|July 30, 2024
Rational combination of cancer therapies with PD1 axis blockadeDaniela S Thommen, Daniel S Peeper
Cancer Cell|April 11, 2018
T Cell Dysfunction in CancerDaniela S Thommen, Ton N Schumacher
International Journal of Clinical Pharmacology and Therapeutics|September 20, 2016
Agonistic anti-CD40 therapy synergizes with LAG-3-blocking antibodies
Philipp Müller, Daniela S Thommen, Alfred Zippelius
Annual Review of Immunology|March 13, 2026
Immune Niches in CancerNadine Slingerland, Eline Runderkamp, Daniela S Thommen
Journal for Immunotherapy of Cancer|August 27, 2020
Rationalizing the pathway to personalized neoadjuvant immunotherapy: the Lombard Street ApproachJudith M Versluis, Daniela S Thommen, Christian U Blank
Nature Reviews. Cancer|February 7, 2020
CD8<sup>+</sup> T cell states in human cancer: insights from single-cell analysisAnne M van der Leun, Daniela S Thommen, Ton N Schumacher
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Immunity|January 17, 2019
The First Shall (Be) Last: Understanding Durable T Cell Responses in ImmunotherapyDaniela S Thommen
Nature Reviews. Cancer|September 27, 2022
Tumour avatars to model patients' responses to immunotherapyDaniela S Thommen
Nature Cancer|September 22, 2022
Keeping track of the T cells that matterPaulien Kaptein, Daniela S Thommen
Science (New York, N.Y.)|January 6, 2022
Tertiary lymphoid structures in cancerTon N Schumacher, Daniela S Thommen
Nature Reviews. Cancer|July 30, 2024
Rational combination of cancer therapies with PD1 axis blockadeDaniela S Thommen, Daniel S Peeper
Cancer Cell|April 11, 2018
T Cell Dysfunction in CancerDaniela S Thommen, Ton N Schumacher
International Journal of Clinical Pharmacology and Therapeutics|September 20, 2016
Agonistic anti-CD40 therapy synergizes with LAG-3-blocking antibodies
Philipp Müller, Daniela S Thommen, Alfred Zippelius
Annual Review of Immunology|March 13, 2026
Immune Niches in CancerNadine Slingerland, Eline Runderkamp, Daniela S Thommen
Journal for Immunotherapy of Cancer|August 27, 2020
Rationalizing the pathway to personalized neoadjuvant immunotherapy: the Lombard Street ApproachJudith M Versluis, Daniela S Thommen, Christian U Blank
Nature Reviews. Cancer|February 7, 2020
CD8<sup>+</sup> T cell states in human cancer: insights from single-cell analysisAnne M van der Leun, Daniela S Thommen, Ton N Schumacher
Pageof 5